Darvon: Review of a Potentially Dangerous Drug

Health & Fitness

  • Author Roger Mcgrady.
  • Published November 14, 2011
  • Word count 561

FDA ANNOUNCES DARVON RECALL: In November 2010, The US Food and Drug Administration announced a nationwide recall of this drug due to its use being linked to a high number of heart problems, as well as overdose and suicide.

DARVON (Darvocet) is reported to have caused serious injury to many thousands of users in the U.S. who have begun filing claims in the U.S. against Xanodyne Pharmaceutical seeking to recover financial compensation as a result of their suffering from heart attacks, strokes, heart rhythm abnormalities (arrhythmia) or other serious injuries and even deaths from the use of this drug.

This pain control medication, with properties similar to codeine, is an enormously popular drug used by millions in the treatment of mild to moderate pain. Also marketed as Darvocet, a compound containing both propoxyphene and acetaminophen, is one of the most popular pain relieving drugs in the U.S. The active medication–propoxyphene–relieves pain by acting on the central nervous system; however, its use has been linked over the years to thousands of deaths and serious injuries, most recently to potentially fatal heart rhythm abnormalities (arrhythmia).

DARVON (Darvocet) FDA BLACK BOX WARNING: The Food and Drug Administration has mandated that all DARVON (Darvocet) packages contain a black box label to warn consumers regarding the higher risks associated with consumption of these drugs.

Have you or a loved one suffered from any of the following serious side effects associated with Darvon

(Darvocet), such as:

  • Heart Attack

  • Stroke

  • Heart Arrythmia

  • Suicide

  • Overdose

  • Death

  • Any other serious side effects

If the answer is yes, a lawyer with experience in the ongoing Darvon (Darvocet) litigation can help evaluate your claim at no charge. The Darvon recall attorneys at JD Law Group are qualified to review your claim. You can contact them directly via 1-888-736-4248 or by going to http://darvon-lawsuitattorney.com/.

DISCLAIMER: The information provided on this website or the web sites linked herein are not a substitute for professional medical or legal advice, diagnosis or treatment. In addition, viewing the content on these websites, requesting additional information, or transmitting information through a contact form does not form an attorney-client relationship with the sponsoring attorney. Any results set forth herein are based upon the facts of that particular case or scientific study and do not represent a promise or guaranty regarding similar outcome or causes. The information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. This firm is licensed to practice law only in the state of California, but is affiliated with a network of licensed attorneys in other states.

Medical Disclaimer

Always seek professional medical advice from a qualified health care practitioner. The information provided on this web site should not be substituted for the diagnosis or treatment of any medical condition. The medical information provided here is of a general nature only, and is not a substitute for professional medical advice. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Drug-Recalls.org and JD Law

Group makes no representation or warranty regarding the accuracy, reliability, completeness,currentness, or timeliness of the content, text or graphics. Links to other sites are provided forinformation only — they do not constitute endorsements of those other sites.

This article is brought to you by the Darvon and Darvocet recall attorneys at JD Law Group. You can reach us directly at 1-888-736-4248 or by going to http://www.drug-recalls.org/darvondarvocet/ with any potential claims.

Article source: https://articlebiz.com
This article has been viewed 637 times.

Rate article

Article comments

There are no posted comments.

Related articles